Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pfizer offers lifeline: ongoing crizotinib access for cancer patients

NCT ID NCT05160922

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study allows people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from crizotinib in a previous Pfizer study to keep receiving the drug after that study ends. About 27 participants will continue treatment while doctors monitor for side effects. The goal is to provide ongoing access and gather more safety information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

27 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants must meet the following key inclusion criteria to be eligible for enrollment into the study: 1. Any participant who is receiving crizotinib and deriving clinical benefit (as determined by their doctor) in a Crizotinib Study which is planned to close. 2. Participants must agree to follow the reproductive criteria as outlined in protocol. 3. No ongoing Grade ≥3 or intolerable Grade 2 AEs considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion #4. 4. Adult Participants (≥18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days. Pediatric Participants (\<18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days. Exclusion Criteria Participants with any of the following characteristics/conditions will be excluded: 1. Female participants who are pregnant or breastfeeding. 2. Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma inflammatory myofibroblastic tumor non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCL IMT NSCLC

Contacts and locations

Locations

  • ASST Monza

    Monza, MB, 20900, Italy

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, 100021, China

  • Fujian Province Oncology Hospital

    Fuzhou, Fujian, 350014, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130028, China

  • Limited Liability Company "EuroCityClinic"

    Saint Petersburg, 197022, Russia

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, 460-0001, Japan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Shanghai Chest Hospital

    Shanghai, 200030, China

  • Sun Yat-Sen University Cancer center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital of College of Medicine,Zhejiang University

    Hangzhou, Zhejiang, 310003, China

  • The First Affiliated Hospital of Guangzhou Medical University.

    Guangzhou, Guangzhou, 510120, China

  • West China Hospital of Sichuan University

    Wuhou District, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.